Trivalent Iron and Ruthenium Complexes with a Redox Noninnocent (2-Mercaptophenylimino)-methyl-4,6-di-tert-butylphenolate(2-) Ligand

2009 ◽  
Vol 48 (8) ◽  
pp. 3783-3791 ◽  
Author(s):  
Nabarun Roy ◽  
Stephen Sproules ◽  
Thomas Weyhermüller ◽  
Karl Wieghardt
Keyword(s):  
Ruthenium Complexes ◽  
Trivalent Iron ◽  
Redox Noninnocent

An Electrochemical Study of Antineoplastic Gallium, Iron and Ruthenium Complexes with Redox Noninnocent α-N-Heterocyclic Chalcogensemicarbazones

2008 ◽  
Vol 47 (23) ◽  
pp. 11032-11047 ◽  
Author(s):  
Christian R. Kowol ◽  
Erwin Reisner ◽  
Ion Chiorescu ◽  
Vladimir B. Arion ◽  
Markus Galanski ◽  
...  
Keyword(s):  
Ruthenium Complexes ◽  
Electrochemical Study ◽  
Redox Noninnocent

Solid Supported Ruthenium Complexes for Olefin Metathesis

2013 ◽  
Vol 17 (22) ◽  
pp. 2592-2608 ◽  
Author(s):  
Fatma Hamad ◽  
Cheng Kai ◽  
Yuan Cai ◽  
Yu Xie ◽  
Yin Lu ◽  
...  
Keyword(s):  
Olefin Metathesis ◽  
Ruthenium Complexes

Synthesis and Biological Evaluations of Organoruthenium Scaffolds: A Comprehensive Update

2018 ◽  
Vol 15 (2) ◽  
pp. 179-207
Author(s):  
Ashaparna Mondal ◽  
Priyankar Paira
Keyword(s):  
Singlet Oxygen ◽  
Anticancer Agents ◽  
Ruthenium Complexes ◽  
Chemotherapeutic Agents ◽  
Quantum Yields ◽  
Ros Generation ◽  
Standard Drug ◽  
Cellular Environment ◽  
Theranostic Agents

Background: Currently ruthenium complexes are immerging as effective anticancer agents due to their less toxicity, better antiproliferative and antimetastatic activity, better stability in cellular environment and most importantly variable oxidation and co-ordination states of ruthenium allows binding this molecule with a variety of ligands. So in past few years researchers have shifted their interest towards organoruthenium complexes having good fluorescent profile that may be applicable for cancer theranostics. Nowadays, photodynamic therapy has become more acceptable because of its easy and effective approach towards killing cancer cells. Objective: Objective of this review article is to shed light on synthesis, characterization, stability and fluorescence studies of various ruthenium [Ru(II) and Ru(III)] complexes and different bioactivity studies conducted with the synthesized compounds to test their candidacy as potent chemotherapeutic agents. Methods: Various heterocyclic ligands containing N,O and S as heteroatom mainly were prepared and subjected to complexation with ruthenium-p-cymene moiety. In most cases [Ru(η6-p-cymene)(µ-Cl)Cl]2 was used as ruthenium precursor and the reactions were conducted in various alcohol medium such as methanol, ethanol or propanol. The synthesized complexes were characterized by 1H NMR and 13C NMR spectroscopy, GC-MS, ESI-MS, elemental analysis and single crystal X-ray crystallography methods. Fluorescence study and stability study were conducted accordingly using water, PBS buffer or DMSO. Stable compounds were considered for cell viability studies. To study the efficacy of the compounds in ROS generation as photosensitizers, in few cases, singlet oxygen quantum yields in presence of light were calculated. Suitable compounds were selected for in vitro & in vivo antiproliferative, anti-invasive activity studies. Result: Many newly synthesized compounds were found to have less IC50 compared to a standard drug cysplatin. Those compounds were also stable preferably in physiological conditions. Good fluorescence profile and ROS generation ability were observed for few compounds. Conclusion: Numerous ruthenium complexes were developed which can be used as cancer theranostic agents. Few molecules were synthesized as photosensitizers which were supposed to generate reactive singlet oxygen species in targeted cellular environment in presence of a particular type of light and thereby ceasing cancer cell growth.

Light activation of cyclometalated ruthenium complexes drives towards caspase 3 dependent apoptosis in gastric cancer cells

2020 ◽  
Vol 208 ◽  
pp. 111080 ◽  
Author(s):  
Jorge Andrés Solís-Ruiz ◽  
Anaïs Barthe ◽  
Gilles Riegel ◽  
Rafael Omar Saavedra-Díaz ◽  
Christian Gaiddon ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Cells ◽  
Caspase 3 ◽  
Ruthenium Complexes ◽  
Light Activation ◽  
Gastric Cancer Cells

Fine‐feature Modifications to Strained Ruthenium Complexes Radically Alter Their Hypoxic Anticancer Activity †

2021 ◽  
Author(s):  
Houston D. Cole ◽  
John A. Roque ◽  
Liubov M. Lifshits ◽  
Rachel Hodges ◽  
Patrick C. Barrett ◽  
...  
Keyword(s):  
Anticancer Activity ◽  
Ruthenium Complexes

Synthesis, characterization and photovoltaic studies of 2,2′;6′,2ʺ-terpyridine-based ruthenium complexes with phenylamino, anthranyl and furfuryl substitutions at the 4′-position

2021 ◽  
pp. 1-17
Author(s):  
Binitendra Naath Mongal ◽  
Sayantani Bhattacharya ◽  
Tarun Kanti Mandal ◽  
Jayati Datta ◽  
Subhendu Naskar
Keyword(s):  
Ruthenium Complexes

Ruthenium Complexes with Chiral Tetradentate Imino−Sulfoxide Ligands

2003 ◽  
Vol 42 (19) ◽  
pp. 5863-5870 ◽  
Author(s):  
Chui-Ying Lai ◽  
Wing-Leung Mak ◽  
Eddie Y. Y. Chan ◽  
Yiu-Keung Sau ◽  
Qian-Feng Zhang ◽  
...  
Keyword(s):  
Ruthenium Complexes

( Z )‐Selective Hydrosilylation and Hydroboration of Terminal Alkynes Enabled by Ruthenium Complexes with an N‐Heterocyclic Carbene Ligand

2021 ◽  
Author(s):  
Yuichiro Mutoh ◽  
Kensuke Yamamoto ◽  
Yusei Mohara ◽  
Shinichi Saito
Keyword(s):  
Ruthenium Complexes ◽  
Terminal Alkynes

Syntheses and crystal structures of new mononuclear and binuclear ruthenium complexes supported by salicylaldimine ligands

2021 ◽  
Author(s):  
Zhiqiang Hao ◽  
Ying Li ◽  
Zhihong Ma ◽  
Jin Lin ◽  
Guo-Liang Lu
Keyword(s):  
Crystal Structures ◽  
Ruthenium Complexes
Sign in / Sign up

Export Citation Format

Share Document